Can the yellow fever vaccine and dengue vaccine be given together, and what are the eligibility criteria and timing for each?

Yellow Fever and Dengue Vaccines: Co-Administration and Eligibility

Yellow fever vaccine (YF-17D) and dengue vaccine (TAK-003/Qdenga®) can be safely administered concomitantly or sequentially, with demonstrated immunogenicity and safety profiles, though a 4-week interval between live vaccines is recommended when not given simultaneously 1.

Co-Administration Evidence

The most recent high-quality evidence from a 2023 phase 3 randomized controlled trial directly addresses this question 2. This study in 900 healthy adults demonstrated:

• Concomitant administration of YF-17D and TAK-003 dengue vaccine was non-inferior to separate administration for yellow fever seroprotection (99.1% vs 99.5%)
• Sequential administration was equally safe and immunogenic
• No important safety risks were identified with either approach
• The only exception was a slightly lower response to DENV-1 with concomitant administration (though GMTs remained similar to other TAK-003 trials)

Practical Administration Guidelines

If giving vaccines together:

• Administer using separate syringes at separate injection sites 1
• Never combine or mix the vaccines in the same syringe
• Both vaccines maintain their immunogenicity when co-administered 2, 3

If giving vaccines separately:

• Wait at least 4 weeks between administration of YF-17D and other live vaccines when not given concomitantly 1
• This interval applies to both yellow fever and dengue vaccines as both are live-attenuated

Yellow Fever Vaccine Eligibility

Recommended Recipients

• Persons aged ≥9 months traveling to or living in endemic areas of South America and Africa 4
• Laboratory workers handling virulent yellow fever virus 1

Absolute Contraindications

• Age <6 months (rates of serious neurologic adverse events: 50-400 per 100,000) 4
• Severe immunodeficiency including:
  • Symptomatic HIV or CD4 counts <200/mm³ (or <15% in children <6 years) 4
  • Primary immunodeficiencies 4
  • Thymus disorders 4
  • Malignant neoplasms affecting bone marrow or lymphatic systems 4
  • Immunosuppressive/immunomodulatory therapy (≥2 weeks of ≥20 mg/day prednisone or equivalent, chemotherapy, TNF-α inhibitors, monoclonal antibodies) 4
  • Solid organ or hematopoietic stem cell transplant recipients within 2 years or still on immunosuppressants 4

Precautions (Risk-Benefit Assessment Required)

• Age 6-8 months: Two cases of neurologic adverse events reported; postpone travel if possible 4
• Age ≥60 years (especially first-time recipients):
  • Serious adverse event rate: 8.3 per 100,000 vs 4.7 per 100,000 overall 4
  • YEL-AND rate: 1.8 per 100,000 vs 0.8 per 100,000 overall
  • YEL-AVD rate: 1.4 per 100,000 vs 0.4 per 100,000 overall
• Asymptomatic HIV with moderate immunosuppression (CD4 200-499/mm³): Consider serologic testing post-vaccination to confirm response 4

Dosing

• Primary vaccination: Single 0.5 mL subcutaneous injection 1
• Booster doses: Generally not needed for most travelers; a single dose provides long-lasting protection 1, 5
• Exceptions for boosters: Laboratory personnel with ongoing exposure, travelers to highly endemic areas (e.g., rural West Africa) after ≥10 years, or country entry requirements 1

Dengue Vaccine Eligibility

Key Principle: Prior Dengue Infection Required

Live-attenuated dengue vaccines (Dengvaxia®, Qdenga®) should primarily be administered to individuals with confirmed prior dengue infection to mitigate antibody-dependent enhancement (ADE) risk 6.

Recommended Recipients

• Individuals aged 9-45 years (Dengvaxia®) or 4+ years (Qdenga®) with laboratory-confirmed prior dengue infection
• Residents of dengue-endemic areas
• Travelers with documented prior dengue infection planning extended stays in endemic regions

Contraindications

• Immunocompromised individuals (same criteria as yellow fever vaccine) 6
• Pregnant women 6
• Individuals without confirmed prior dengue infection (due to ADE risk)

Important Caveat: Cross-Reactive Immunity

Recent evidence suggests prior flavivirus immunity (including from yellow fever vaccination) can skew immune responses toward cross-reactive antibodies with potential for dengue ADE 7. However, the 2023 clinical trial showed no clinically significant safety concerns with co-administration 2. This remains an area requiring clinical judgment, particularly in flavivirus-naïve individuals receiving both vaccines.

Clinical Algorithm

For travelers requiring both vaccines:

1. Assess yellow fever risk based on destination and duration
2. Assess dengue risk and prior infection status (requires serologic confirmation ideally)
3. Screen for contraindications to both vaccines (immunosuppression, pregnancy, age)
4. Choose administration strategy:
   • Preferred: Concomitant administration if both vaccines indicated simultaneously
   • Alternative: Sequential with ≥4-week interval if scheduling allows
5. Provide medical waiver if contraindications exist but travel unavoidable 4
6. Observe 15 minutes post-vaccination for immediate reactions 4

Common Pitfalls to Avoid

• Do not mix vaccines in the same syringe
• Do not administer yellow fever vaccine to severely immunocompromised patients
• Do not give dengue vaccine to dengue-naïve individuals without careful risk assessment
• Do not use expired or improperly reconstituted yellow fever vaccine (must use within 60 minutes) 1
• Do not forget to validate International Certificate of Vaccination (ICVP) with proper stamp and signature 4